0001209191-20-033320.txt : 20200601 0001209191-20-033320.hdr.sgml : 20200601 20200601214254 ACCESSION NUMBER: 0001209191-20-033320 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200528 FILED AS OF DATE: 20200601 DATE AS OF CHANGE: 20200601 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DRACHMAN JONATHAN G CENTRAL INDEX KEY: 0001588467 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38800 FILM NUMBER: 20935477 MAIL ADDRESS: STREET 1: 21823 30TH DRIVE SE CITY: BOTHELL STATE: WA ZIP: 98021 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Harpoon Therapeutics, Inc. CENTRAL INDEX KEY: 0001708493 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473458693 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 131 OYSTER POINT BOULEVARD STREET 2: SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-443-7400 MAIL ADDRESS: STREET 1: 131 OYSTER POINT BOULEVARD STREET 2: SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-05-28 0 0001708493 Harpoon Therapeutics, Inc. HARP 0001588467 DRACHMAN JONATHAN G C/O HARPOON THERAPEUTICS, INC. 131 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Director Stock Option (Right to Buy) 20.59 2020-05-28 4 A 0 10167 0.00 A 2030-05-27 Common Stock 10167 10167 D Director Stock Option (Right to Buy) 20.59 2020-05-28 4 A 0 2880 0.00 A 2030-05-27 Common Stock 2880 2880 D The stock option will fully vest and become exercisable on May 28, 2021, subject to the continuous service of the Reporting Person with the Issuer on such date. The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the last day of each calendar quarter following the grant date of May 28, 2020 (on June 30, 2020, September 30, 2020, December 31, 2020, and March 31, 2021), subject to the continuous service of the Reporting Person on each vesting date. /s/ Jonathan Drachman by Christopher Whitmore, Attorney-in-Fact 2020-06-01